News Release

（Amendment）GNI Group Receives Manufacture Approval for F647 from China FDA for First Idiopathic Pulmonary Fibrosis Drug in China

（Amendment）GNI Group Receives Manufacture Approval for F647 from China FDA for First Idiopathic Pulmonary Fibrosis Drug in China

GNI Group Receives Manufacture Approval for F647 from China FDA for First Idiopathic Pulmonary Fibrosis Drug in China
Notice for Exercise of the 37th Round of Stock Options in December, 2013